Inmune Bio Inc (INMB) - News Archive

Revolutionary Partnership Aims to Transform Alzheimer’s Trial Operations with Advanced AI TechnologyIn a groundbreaking announcement, OmniScience Inc. and INmune Bio Inc. (NASDAQ: INMB) have unveiled a pioneering partne...

INmune Bio Inc. Completes Enrollment in Pivotal Phase 2 Trial for Alzheimer’s Disease: A Step Towards Innovative Treatments Boca Raton, Florida, Nov. 13, 2024 - INmune Bio Inc. (NASDAQ: INMB), a clinical-stage company a...

: In a significant move to bolster its financial resources and advance its pioneering treatments, INmune Bio Inc. (Nasdaq: INMB) has successfully closed a $13.0 million registered direct offering. This capital influx is...

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer s Disease TrialIn a recent press release, INmune Bio, Inc. announced the completion of a blinded interim analysis of their Phase II clinical tria...

INmune Bio Inc. Advances Revolutionary INKmune Cell Therapy in Metastatic Castration-Resistant Prostate Cancer StudyBoca Raton, Florida, April 29, 2024 - INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology comp...

INmune Bio, Inc., a Florida-based clinical-stage immunology corporation, has reported its conclusive agreements for a registered direct offering valued at $9.7 million. The offering is priced at-the-market under NASDAQ...